10338 studies found for:    NCI
Show Display Options
Rank Status Study
1 Completed Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Duct Cell Adenocarcinoma of the Pancreas;   Stage IV Pancreatic Cancer
Interventions: Drug: bortezomib;   Drug: gemcitabine hydrochloride
2 Completed Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
Condition: Head and Neck Cancer
Interventions: Biological: filgrastim;   Drug: fluorouracil;   Drug: hydroxyurea;   Drug: paclitaxel;   Procedure: conventional surgery;   Radiation: radiation therapy
3 Completed Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer;   Thromboembolism
Interventions: Drug: acetylsalicylic acid;   Drug: alvocidib;   Drug: clopidogrel bisulfate
4 Recruiting MLN0128 and Ziv-Aflibercept in Treating Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Somatostatinoma;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: TORC1/2 inhibitor MLN0128;   Biological: ziv-aflibercept;   Other: laboratory biomarker analysis
5 Completed
Has Results
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: tanespimycin
6 Completed Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
Conditions: Recurrent Melanoma;   Stage III Melanoma
Interventions: Drug: isolated limb perfusion;   Drug: melphalan;   Biological: recombinant tumor necrosis factor family protein;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Active, not recruiting Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: belinostat;   Drug: isotretinoin;   Other: pharmacological study
8 Active, not recruiting Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: selumetinib;   Other: laboratory biomarker analysis
9 Completed
Has Results
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Gastrointestinal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: erlotinib hydrochloride;   Biological: bevacizumab
10 Completed Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Intervention: Biological: recombinant interleukin-12
11 Completed
Has Results
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer
Intervention: Drug: sorafenib tosylate
12 Completed Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Condition: Head and Neck Cancer
Intervention: Drug: gefitinib
13 Completed Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
Conditions: Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: filgrastim;   Drug: becatecarin;   Drug: cisplatin
14 Completed A Phase II Study of UCN-01 in Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: 7-hydroxystaurosporine;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Unknown  Lymphocyte Therapy in Treating Patients With Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: aldesleukin;   Biological: muromonab-CD3;   Biological: therapeutic autologous lymphocytes;   Procedure: adjuvant therapy
16 Completed Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Stage III Endometrial Carcinoma;   Stage IV Endometrial Carcinoma
Interventions: Biological: trastuzumab;   Other: laboratory biomarker analysis
17 Completed Resveratrol in Postmenopausal Women With High Body Mass Index
Condition: Healthy, no Evidence of Disease
Interventions: Drug: resveratrol;   Other: laboratory biomarker analysis
18 Completed Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
Conditions: Stage III Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: bryostatin 1;   Drug: cisplatin;   Other: laboratory biomarker analysis
19 Completed Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
20 Recruiting Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Biological: bevacizumab;   Biological: anti-endoglin monoclonal antibody TRC105;   Other: laboratory biomarker analysis;   Other: pharmacological study

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years